[Some pathophysiological aspects of hyperthermic pharmacotherapy and its clinical use].
The use of artificially induced general controllable hyperthermia (GCH) of high degree is acknowledged as the 21st century intensive technology; it is used in the treatment of diseases and conditions that can be hardly cured by routine methods. Pathogenetic pharmacotherapy was made use of to enhance, purposefully, the GCH efficiency. The suggested concept, i.e. reproduction of the most efficient use of positive effects from high temperature and thermally mediated effects of pharmacotherapy, was named as "hyperthermic pharmacotherapy". The controllable maintenance of the "biological zero" phenomenon in the brain (registered by EEG) at 42-44 degrees C is the safety criterion of high-level GCH. The described intensive-care technique can be referred to as promising considering the modern anesthesiological-management potentialities related with GCH safety.